MANGOCEUTICALS, INC. (MGRX) Latest Company News

Oct 9, 2026, 20:15 UTC
MANGOCEUTICALS, INC. issued and sold 657,000 common shares and warrants to purchase up to 657,000 shares at a combined price of $0.75 per share and warrant, for approximately $492,750 in gross proceeds.
Oct 9, 2026, 20:01 UTC
Mangoceuticals closed a registered direct offering priced at a 74% premium to the recent market close.
Source:
- globenewswire.com
Oct 5, 2026, 20:12 UTC
OFA Group appointed Eugene M. Johnston as Chief Financial Officer effective October 1, 2026.
Oct 1, 2026, 19:50 UTC
Mangoceuticals secured a $2.5 million strategic investment in its subsidiary MangoRx IP Holdings and received an initial $1.75 million tranche, with no issuance of MGRX common stock.
Source:
- globenewswire.com
Aug 4, 2026, 20:05 UTC
Nasdaq granted Mangoceuticals, Inc. a 180-day extension to regain compliance with the minimum bid price requirement, extending the deadline to February 1, 2027.
Source:
- globenewswire.com
Jul 30, 2026, 11:00 UTC
Mangoceuticals entered into a definitive business combination agreement with Nuclea Energy Inc. to bring Nuclea's Morpheus microreactor to the public markets.
Source:
- globenewswire.com
- newsfilecorp.com
Jul 30, 2026, 00:00 UTC
Mangocuticals, Inc. terminated Jacob D. Cohen as Chief Executive Officer and appointed Josef Freundorfer as successor, while also appointing Jacob D. Cohen as President and Sagar Sanghera as Executive Chairman and Director.
Jul 2, 2026, 00:00 UTC
MangocEuticals, Inc. completed a private placement of 850,000 shares of restricted common stock to an accredited investor, raising $272,000 at $0.32 per share, exempt from registration under Section 4(a)(2) and Rule 506 of Regulation D.

MGRX

MANGOCEUTICALS, INC. issued and sold 657,000 common shares and warrants to purchase up to 657,000 shares at a combined price of $0.75 per share and warrant, for approximately $492,750 in gross proceeds.

Mangoceuticals closed a registered direct offering priced at a 74% premium to the recent market close.

OFA Group appointed Eugene M. Johnston as Chief Financial Officer effective October 1, 2026.

Mangoceuticals secured a $2.5 million strategic investment in its subsidiary MangoRx IP Holdings and received an initial $1.75 million tranche, with no issuance of MGRX common stock.

Nasdaq granted Mangoceuticals, Inc. a 180-day extension to regain compliance with the minimum bid price requirement, extending the deadline to February 1, 2027.

Mangoceuticals entered into a definitive business combination agreement with Nuclea Energy Inc. to bring Nuclea's Morpheus microreactor to the public markets.

Mangocuticals, Inc. terminated Jacob D. Cohen as Chief Executive Officer and appointed Josef Freundorfer as successor, while also appointing Jacob D. Cohen as President and Sagar Sanghera as Executive Chairman and Director.

MangocEuticals, Inc. completed a private placement of 850,000 shares of restricted common stock to an accredited investor, raising $272,000 at $0.32 per share, exempt from registration under Section 4(a)(2) and Rule 506 of Regulation D.